Amgen cannot stop imminent sale of Neupogen copycat: U.S. appeals court
September 02, 2015 at 11:42 AM EDT
NEW YORK, Sept 2 (Reuters) - A U.S. appeals court has cleared the path for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen.
